Pipeline: New therapies to come for debilitating eye diseases

Article

New drug from Gensight Biologics hits pipeline

GenSight Biologics has developed a therapy for Leber hereditary optic neuropathy (LHON), called Lumevoq. The drug has been submitted for approval in Europe, and the company plans to submit for U.S. Food & Drug Administration approval in late 2021.

Dr. Gilly explains the mechanism of action for Lumevoq and provides a look into the GenSight Biologics pipeline for the future.

Related: Myopia control data and whats to come with Dr. Noel Brennan

Recent Videos
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Billy R. Hammond details the study, which explored how HEV-light filtering, specifically in the 380-440 nanometer range, impacts visual comfort for patients with presbyopia.
Dr. Mark Bullimore investigates myopia in an omnibus model at AAOpt 2024
Dr. Justin Schweitzer busts myths about comanaging ocular surgery
Dr. Justin Schweitzer at AAOpt
Julie Rodman, OD, MS, FAAO, discusses her Rapid Fire session on retinal diseases and conditions at AAOpt 2024
Dr Pedram Hamrah
Related Content
2024 dice Image credit: AdobeStock/SHOHIDGraphics

Year in review: Innovations and insights in refractive optometry and vision care in 2024

Cecelia Koetting, OD, FAAO, DipABO
December 19th 2024
Article
You and Eye by Optometry Times with host Miriam Korik, OD

You and Eye: Myopia cannot be viewed as a specialty in today's practice setting

Miriam Korik, OD;Justin Kwan, OD, FAAO;Emily Kaiser Maharjan, Assistant Managing Editor
October 18th 2024
Podcast
A close up of an eye with Demodex blepharitis - Image credit: Adobe Stock / ©OHishi_Foto

The whys and wherefores of Demodex blepharitis

Lynda Charters
December 12th 2024
Article
You and Eye: Mastering myopia management - with Justin Kwan, OD, FAAO

You and Eye: Mastering myopia management - with Justin Kwan, OD, FAAO

Miriam Korik, OD;Justin Kwan, OD, FAAO;Emily Kaiser Maharjan, Assistant Managing Editor
October 9th 2024
Podcast
Business people shaking hands Image credit: AdobeStock/NAMPIX

Bausch + Lomb acquires ELIOS system, expanding glaucoma treatment options

David Hutton, Managing Editor, Ophthalmology Times
December 11th 2024
Article
Eye drop administration Image credit: AdobeStock/ShutterDivision

Lifitegrast improves clinical signs and biomarkers of patients with DED: A Q&A with Dr. James Thimons

J. James Thimons, OD, FAAO, ABO;Jordana Joy, Associate Editor;Emily Kaiser Maharjan, Assistant Managing Editor
December 11th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.